Baird raised the firm’s price target on Elevance Health (ELV) to $331 from $317 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which suggests its fundamental story is firming up.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- AI Models Turn More Positive on Elevance Health After Guidance Boost
- Elevance Health Earnings Call Highlights Growth, Key Risks
- Elevance Health reports Q1 adjusted EPS $12.58, consensus $10.81
- Elevance Health raises FY26 adjusted EPS view to ‘at least $26.75’
- Elevance Health backs FY26 operating cash flow view ‘at least $5.5B’